Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
Mind Medicine Analyst Ratings and Price Targets | NASDAQ:MNMD | Benzinga
Mind Medicine Inc has a consensus price target of $24.17 based on the ratings of 13 analysts. The high is $55 issued by HC Wainwright & Co. on March 7, 2025. The low is $7 issued by Roth Capital on May 4, 2022. The 3 most-recent analyst ratings were released by Baird, HC Wainwright & Co., and HC Wainwright & Co. on March 7, 2025, March 7, 2025, and January 31, 2025, respectively. With an average price target of $42 between Baird, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 502.52% upside for Mind Medicine Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Baird
HC Wainwright & Co.
Evercore ISI Group
Chardan Capital
Oppenheimer
1calculated from analyst ratings
Analyst Ratings for Mind Medicine
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/07/2025 | Buy Now | 129.53% | Baird | Joel Beatty69% | $27 → $16 | Maintains | Outperform | Get Alert |
| 03/07/2025 | Buy Now | 689.02% | HC Wainwright & Co. | Patrick Trucchio47% | $55 → $55 | Reiterates | Buy → Buy | Get Alert |
| 01/31/2025 | Buy Now | 689.02% | HC Wainwright & Co. | Patrick Trucchio47% | $55 → $55 | Reiterates | Buy → Buy | Get Alert |
| 01/28/2025 | Buy Now | 229.95% | Evercore ISI Group | Gavin Clark-Gartner42% | → $23 | Initiates | → Outperform | Get Alert |
| 12/20/2024 | Buy Now | 186.92% | Chardan Capital | Rudy Li17% | → $20 | Initiates | → Buy | Get Alert |
| 12/17/2024 | Buy Now | 186.92% | Oppenheimer | Francois Brisebois44% | $20 → $20 | Reiterates | Outperform → Outperform | Get Alert |
| 11/11/2024 | Buy Now | 689.02% | HC Wainwright & Co. | Patrick Trucchio47% | $55 → $55 | Reiterates | Buy → Buy | Get Alert |
| 09/16/2024 | Buy Now | 100.84% | Canaccord Genuity | Sumant Kulkarni43% | $16 → $14 | Maintains | Buy | Get Alert |
| 08/29/2024 | Buy Now | 689.02% | HC Wainwright & Co. | Patrick Trucchio47% | $35 → $55 | Maintains | Buy | Get Alert |
| 07/31/2024 | Buy Now | 402.1% | HC Wainwright & Co. | Patrick Trucchio47% | $35 → $35 | Reiterates | Buy → Buy | Get Alert |
| 07/24/2024 | Buy Now | 416.45% | Roth MKM | Jason Wittes53% | $36 → $36 | Maintains | Buy | Get Alert |
| 06/21/2024 | Buy Now | — | Cantor Fitzgerald | Charles Duncan72% | — | Reiterates | → Overweight | Get Alert |
| 06/05/2024 | Buy Now | 215.61% | RBC Capital | Brian Abrahams52% | $22 → $22 | Reiterates | Outperform → Outperform | Get Alert |
| 05/28/2024 | Buy Now | 287.34% | Baird | Joel Beatty69% | → $27 | Initiates | → Outperform | Get Alert |
| 05/24/2024 | Buy Now | 402.1% | HC Wainwright & Co. | Patrick Trucchio47% | $35 → $35 | Reiterates | Buy → Buy | Get Alert |
| 05/13/2024 | Buy Now | 186.92% | Oppenheimer | Francois Brisebois44% | $29 → $20 | Reiterates | Outperform → Outperform | Get Alert |
| 05/10/2024 | Buy Now | 402.1% | HC Wainwright & Co. | Patrick Trucchio47% | $75 → $35 | Maintains | Buy | Get Alert |
| 04/15/2024 | Buy Now | 186.92% | Leerink Partners | Rudy Li17% | → $20 | Initiates | → Outperform | Get Alert |
| 03/14/2024 | Buy Now | 975.93% | HC Wainwright & Co. | Patrick Trucchio47% | $75 → $75 | Reiterates | Buy → Buy | Get Alert |
| 03/08/2024 | Buy Now | 215.61% | RBC Capital | Brian Abrahams52% | $15 → $22 | Maintains | Outperform | Get Alert |
| 03/07/2024 | Buy Now | 416.45% | Roth MKM | Jonathan Aschoff34% | $25 → $36 | Maintains | Buy | Get Alert |
| 03/01/2024 | Buy Now | 975.93% | HC Wainwright & Co. | Patrick Trucchio47% | $75 → $75 | Reiterates | Buy → Buy | Get Alert |
| 02/29/2024 | Buy Now | 115.19% | RBC Capital | Brian Abrahams52% | $14 → $15 | Maintains | Outperform | Get Alert |
| 10/23/2023 | Buy Now | 0.42% | RBC Capital | Brian Abrahams52% | → $7 | Reiterates | Outperform → Outperform | Get Alert |
| 08/22/2023 | Buy Now | 0.42% | Cantor Fitzgerald | Charles Duncan72% | → $7 | Reiterates | Overweight → Overweight | Get Alert |
| 08/04/2023 | Buy Now | 975.93% | HC Wainwright & Co. | Patrick Trucchio47% | → $75 | Reiterates | → Buy | Get Alert |
| 08/04/2023 | Buy Now | 0.42% | RBC Capital | Brian Abrahams52% | $5 → $7 | Maintains | Outperform | Get Alert |
| 08/04/2023 | Buy Now | 201.26% | EF Hutton | Elemer Piros56% | → $21 | Reiterates | Buy → Buy | Get Alert |
| 07/10/2023 | Buy Now | -28.27% | RBC Capital | Brian Abrahams52% | → $5 | Reiterates | Outperform → Outperform | Get Alert |
| 06/28/2023 | Buy Now | 975.93% | HC Wainwright & Co. | Patrick Trucchio47% | $75 → $75 | Reiterates | Buy → Buy | Get Alert |
| 06/21/2023 | Buy Now | -28.27% | RBC Capital | Brian Abrahams52% | → $5 | Reiterates | Outperform → Outperform | Get Alert |
| 06/20/2023 | Buy Now | 201.26% | EF Hutton | Elemer Piros56% | → $21 | Reiterates | Buy → Buy | Get Alert |
| 05/18/2023 | Buy Now | 0.42% | Cantor Fitzgerald | Charles Duncan72% | → $7 | Reiterates | → Overweight | Get Alert |
| 05/18/2023 | Buy Now | 201.26% | EF Hutton | Elemer Piros56% | → $21 | Reiterates | Buy → Buy | Get Alert |
| 05/09/2023 | Buy Now | 975.93% | HC Wainwright & Co. | Patrick Trucchio47% | → $75 | Reiterates | → Buy | Get Alert |
| 05/05/2023 | Buy Now | 201.26% | EF Hutton | Elemer Piros56% | → $21 | Reiterates | → Buy | Get Alert |
| 04/18/2023 | Buy Now | 975.93% | HC Wainwright & Co. | Patrick Trucchio47% | → $75 | Reiterates | → Buy | Get Alert |
| 04/14/2023 | Buy Now | 215.61% | Oppenheimer | Francois Brisebois44% | → $22 | Reiterates | → Outperform | Get Alert |
| 04/14/2023 | Buy Now | 201.26% | EF Hutton | Elemer Piros56% | → $21 | Reiterates | → Buy | Get Alert |
| 03/16/2023 | Buy Now | 975.93% | HC Wainwright & Co. | Patrick Trucchio47% | → $75 | Reiterates | → Buy | Get Alert |
| 03/10/2023 | Buy Now | -28.27% | RBC Capital | Brian Abrahams52% | → $5 | Reiterates | → Outperform | Get Alert |
| 03/10/2023 | Buy Now | 201.26% | EF Hutton | Elemer Piros56% | → $21 | Reiterates | → Buy | Get Alert |
| 01/19/2023 | Buy Now | 975.93% | HC Wainwright & Co. | Patrick Trucchio47% | → $75 | Reiterates | → Buy | Get Alert |
| 12/16/2022 | Buy Now | 201.26% | EF Hutton | Elemer Piros56% | → $21 | Initiates | → Buy | Get Alert |
| 11/16/2022 | Buy Now | -28.27% | RBC Capital | Brian Abrahams52% | → $5 | Initiates | → Outperform | Get Alert |
| 09/21/2022 | Buy Now | 975.93% | HC Wainwright & Co. | Patrick Trucchio47% | $5 → $75 | Maintains | Buy | Get Alert |
| 08/26/2022 | Buy Now | -49.79% | Oppenheimer | Francois Brisebois44% | → $52.5 | Initiates | → Outperform | Get Alert |
| 08/16/2022 | Buy Now | -28.27% | HC Wainwright & Co. | Patrick Trucchio47% | $150 → $75 | Maintains | Buy | Get Alert |
| 05/04/2022 | Buy Now | 0.42% | Roth Capital | Elemer Piros56% | → $105 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Mind Medicine (MNMD) stock?
The latest price target for Mind Medicine (NASDAQ:MNMD) was reported by Baird on March 7, 2025. The analyst firm set a price target for $16.00 expecting MNMD to rise to within 12 months (a possible 129.53% upside). 18 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Mind Medicine (MNMD)?
The latest analyst rating for Mind Medicine (NASDAQ:MNMD) was provided by Baird, and Mind Medicine maintained their outperform rating.
When was the last upgrade for Mind Medicine (MNMD)?
There is no last upgrade for Mind Medicine
When was the last downgrade for Mind Medicine (MNMD)?
There is no last downgrade for Mind Medicine.
When is the next analyst rating going to be posted or updated for Mind Medicine (MNMD)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Mind Medicine, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Mind Medicine was filed on March 7, 2025 so you should expect the next rating to be made available sometime around March 7, 2026.
Is the Analyst Rating Mind Medicine (MNMD) correct?
While ratings are subjective and will change, the latest Mind Medicine (MNMD) rating was a maintained with a price target of $27.00 to $16.00. The current price Mind Medicine (MNMD) is trading at is $6.97, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.